Disorders of the Anterior Pituitary and Hypothalamus
kaiser_becerra
2,943 views
37 slides
Jan 08, 2016
Slide 1 of 37
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
About This Presentation
Disorders of the Anterior Pituitary and Hypothalamus, review of Harrison's Principles of Internal Medicine.
Size: 6.86 MB
Language: en
Added: Jan 08, 2016
Slides: 37 pages
Slide Content
Disorders of the Anterior Pituitary and Hypothalamus DR. JUAN CARLOS BECERRA MARTÍNEZ CÁTEDRA DE MEDICINA INTERNA-MC3087 Tecnológico de Monterrey Campus Guadalajara
Anterior Pituitary Hormone Expression and Regulation Harrison’s 18th Edition.
Etiology of Hypopituitarism Harrison’s 18th Edition. Trophic hormone failure associated with pituitary compression or destruction usually occurs sequentially: GH > FSH > LH > TSH > ACTH. During childhood, growth retardation is often the presenting feature, and in adults, hypogonadism is the earliest symptom.
Tests of Pituitary Sufficiency Harrison’s 18th Edition.
Tests of Pituitary Sufficiency Harrison’s 18th Edition.
Tests of Pituitary Sufficiency Harrison’s 18th Edition.
Hypothalamic, Pituitary, and Other Sellar Masses Harrison’s 18th Edition.
Hypothalamic, Pituitary, and Other Sellar Masses Harrison’s 18th Edition.
Features of Sellar Mass Lesions Harrison’s 18th Edition.
Features of Sellar Mass Lesions Harrison’s 18th Edition.
Features of Sellar Mass Lesions Harrison’s 18th Edition.
Features of Sellar Mass Lesions Harrison’s 18th Edition.
Screening Tests for Functional Pituitary Adenomas Harrison’s 18th Edition.
Treatment: Transsphenoidal Surgery Harrison’s 18th Edition.
Treatment: Transsphenoidal Surgery Harrison’s 18th Edition.
Treatment: Prolactinoma Harrison’s 18th Edition.
Treatment: Prolactinoma Harrison’s 18th Edition. Oral dopamine agonists ( cabergoline and bromocriptine ) are the mainstay of therapy for patients with micro- or macroprolactinomas . Dopamine agonists suppress PRL secretion and synthesis as well as lactotrope cell proliferation.
Management of Acromegaly Harrison’s 18th Edition. Somatostatin Analogues Octreotide Lanreotide , Sandostatin -LAR is a sustained-release, long-acting formulation of octreotide incorporated into microspheres that sustain drug levels for several weeks after intramuscular injection.
Management of Acromegaly Harrison’s 18th Edition. GH Receptor Antagonist Pegvisomant antagonizes endogenous GH action by blocking peripheral GH binding to its receptor.
ACTH Deficiency Harrison’s 18th Edition. The total daily dose of hydrocortisone replacement preferably should not exceed 25 mg daily, divided into two or three doses. Prednisone (5 mg each morning) is longer-acting and has fewer mineralocorticoid effects than hydrocortisone.
Cushing's Syndrome (ACTH- Producing Adenoma) Harrison’s 18th Edition. Ketoconazole , an imidazole derivative antimycotic agent , inhibits several P450 enzymes and effectively lowers cortisol in most patients with Cushing's disease when administered twice daily (600–1200 mg/d). Metyrapone (2–4 g/d) inhibits 11-hydroxylase activity and normalizes plasma cortisol in up to 75% of patients . Mitotane ( o , p ′-DDD; 3–6 g/d orally in four divided doses) suppresses cortisol hypersecretion by inhibiting 11-hydroxylase Other agents include aminoglutethimide (250 mg tid ), trilostane (200–1000 mg/d), cyproheptadine (24 mg/d), and IV etomidate (0.3 mg/kg per hour ).